RET
ENSG00000165731
Target class
Kinase
Chromosome
10
Approved drugs
9
Clinical candidates (approved and in development)
15
- Approved drugs
- 9
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 15
- Chemical probe available
- Yes
- Target name
- RET
- Gene name
- Ret proto-oncogene
- Gene symbol
- RET
- Protein name
- Proto-oncogene tyrosine-protein kinase receptor Ret (EC 2.7.10.1) (Cadherin family member 12) (Proto-oncogene c-Ret) [Cleaved into: Soluble RET kinase fragment; Extracellular cell-membrane anchored RET cadherin 120 kDa fragment]
- PTC
- CDHF12
- RET51
- CDHR16
- HSCR1
- MEN2A
- MTC1
- MEN2B
- Gene biotype
- Protein coding
- Gene family
- Cadherin related|Receptor tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 21
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 6.3
- Tissue specificity (Gini)
- 0.497
- Tissue specificity (tau)
- 0.806
- KEGG gene identifiers
- hsa:5979
- Protein interaction confidence
- 0.851297
- Protein interaction partners
- 64
- R-HSA-5673001
- R-HSA-8853659
- R-HSA-9768919
- R-HSA-9830364
- R-HSA-9830674
- End position
- 43130351
- Start position
- 43077026
- Chromosome
- 10
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein . Endosome membrane
- Single-pass type I membrane protein . Note=Predominantly located on the plasma membrane (PubMed:23333276, PubMed:9575150). In the presence of SORL1 and GFRA1, directed to endosomes (PubMed:23333276). .
- Cytosol
- Golgi apparatus
- Plasma membrane
- PubMed 19823924
- PubMed 21994944
- PubMed 23333276
- PubMed 28953886
- PubMed 9575150
- Tissue specificity (tau)
- 0.8056
- Expression inequality (Gini)
- 0.496994
Expression in transcripts per million
- Brain - Substantia nigra
- 6.3
- Pituitary
- 4.82
- Brain - Cerebellum
- 4.03
- Colon - Sigmoid
- 4.02
- Brain - Frontal Cortex (BA9)
- 3.76
Expression in transcripts per million
- Brain - Substantia nigra6.3
- Pituitary4.82
- Brain - Cerebellum4.03
- Colon - Sigmoid4.02
- Brain - Frontal Cortex (BA9)3.76
- Brain - Hypothalamus3.73
- Testis3.25
- Brain - Cerebellar Hemisphere2.8
- Brain - Cortex2.76
- Colon - Transverse1.9
- Esophagus - Muscularis1.87
- Brain - Anterior cingulate cortex (BA24)1.86
- Stomach1.8
- Esophagus - Gastroesophageal Junction1.77
- Cervix - Endocervix1.72
- Prostate1.47
- Vagina1.39
- Cervix - Ectocervix1.25
- Adipose - Visceral (Omentum)1.2
- Adrenal Gland1.17
- Small Intestine - Terminal Ileum1.02
- Breast - Mammary Tissue0.99
- Adipose - Subcutaneous0.98
- Thyroid0.94
- Uterus0.94
And 29 more, listed on the interactive page.
- GO:0007158
- GO:0007165
- GO:0007411
- GO:0007497
- GO:0010976
- GO:0030155
- GO:0030335
- GO:0033619
- GO:0033630
- GO:0035860
- GO:0043410
- GO:0051897
- GO:0071300
- GO:0160144
- GO:2001241
- GO:0005886
- GO:0010008
- GO:0043235
- GO:0098797
- GO:0004713
- GO:0004714
- GO:0005509
- GO:0005515
- GO:0038023
Related records
Trials (1,801)
- "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
- (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
- [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
- [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
- [68 Ga]-DOTANOC PET/CT in GEP-NETs
- [68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas
- [68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
- 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)
- 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
- 18F-DCFBC PET/CT in Prostate Cancer
- 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma
- 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
- 68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis
- 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.
- 68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC
Drugs (18)
- Alectinib Tyrosine-protein kinase receptor RET inhibitor
- Alectinib hydrochloride Tyrosine-protein kinase receptor RET inhibitor
- AST-487 Tyrosine-protein kinase receptor RET inhibitor
- BOS-589 Tyrosine-protein kinase receptor RET inhibitor
- CEP-2563 Tyrosine-protein kinase receptor RET inhibitor
- Cep-2563 dihydrochloride Tyrosine-protein kinase receptor RET inhibitor
- CEP-32496 Tyrosine-protein kinase receptor RET inhibitor
- Lestaurtinib Tyrosine-protein kinase receptor RET inhibitor
- Motesanib Tyrosine-protein kinase receptor RET inhibitor
- Pralsetinib Tyrosine-protein kinase receptor RET inhibitor
- Quizartinib Tyrosine-protein kinase receptor RET inhibitor
- Regorafenib Tyrosine-protein kinase receptor RET inhibitor
- Selpercatinib Tyrosine-protein kinase receptor RET inhibitor
- Sorafenib Tyrosine-protein kinase receptor RET inhibitor
- Sorafenib tosylate Tyrosine-protein kinase receptor RET inhibitor
- Sunitinib Tyrosine-protein kinase receptor RET inhibitor
- Sunitinib malate Tyrosine-protein kinase receptor RET inhibitor
- Vandetanib Tyrosine-protein kinase receptor RET inhibitor